Preclinical pharmacokinetic investigation of the bioavailability and skin distribution of HY-072808 ointment, a novel drug candidate for the treatment of atopic dermatitis, in minipigs by a newly LC-MS/MS method

References

• Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM, Freitas CS, Marcon R, Calixto JB. 2016. Non-clinical studies in the process of new drug development - Part II: good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz J Med Biol Res. 49(12):e5646. doi:10.1590/1414-431X20165646.
   PubMed Web of Science ®Google Scholar
• Au WL, Skinner MF, Benfeldt E, Verbeeck RK, Kanfer I. 2012. Application of dermal microdialysis for the determination of bioavailability of clobetasol propionate applied to the skin of human subjects. Skin Pharmacol Physiol. 25(1):17–24. doi:10.1159/000330489.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC-H, Rubel D, et al. 2017. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (Liberty AD Chronos): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 389(10086):2287–2303. Doi:10.1016/S0140-6736(17)31191-1
   PubMed Web of Science ®Google Scholar
• Briscoe CJ, Hage DS. 2009. Factors affecting the stability of drugs and drug metabolites in biological matrices. Bioanalysis. 1(1):205–220. doi:10.4155/bio.09.20.
   PubMed Web of Science ®Google Scholar
• Chen ZH, Zhang SX, Long N, Lin LS, Chen T, Zhang FP, Lv XQ, Ye PZ, Li N, Zhang KZ. 2016. An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s. Acta Pharmacol Sin. 37(5):708–718. doi:10.1038/aps.2016.10.
   PubMed Web of Science ®Google Scholar
• Chu Z, Xu Q, Zhu Q, Ma X, Mo J, Lin G, Zhao Y, Gu Y, Bian L, Shao L, et al. 2021. Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis. Eur J Med Chem. 213:113171. doi:10.1016/j.emech.2021.113171.
   PubMed Web of Science ®Google Scholar
• Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. 2015. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015(7):CD009864. doi:10.1002/14651858.CD009864.pub2.
   PubMedGoogle Scholar
• Debeer S, Le Luduec JB, Kaiserlian D, Laurent P, Nicolas JF, Dubois B, Kanitakis J. 2013. Comparative histology and immunohistochemistry of porcine versus human skin. Eur J Dermatol. 23(4):456–466. doi:10.1684/ejd.2013.2060.
   PubMed Web of Science ®Google Scholar
• Dhar S, Seth J, Parikh D. 2014. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 59(5):460–464. doi:10.4103/0019-5154.139874.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Call RS, Forsha DW, Fowler J, Hebert AA, Spellman M, Stein Gold LF, Van Syoc M, Zane LT, Tschen E, et al. 2017. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 77(4):641–649. e5. doi:10.1016/j.jaad.2017.06.010.
   PubMed Web of Science ®Google Scholar
• Feng X, Deng Z, Chen J, Ding Y, Zheng H. 2023. A validated UHPLC-MS/MS assay for rapid and sensitive determination of crisaborale in human plasma and its clinico-pharmacokinetic application. J Pharm Biomed Anal. 223:115129. doi:10.1016/j.jpba.2022.115129.
   PubMed Web of Science ®Google Scholar
• Halling-Overgaard AS, Kezic S, Jakasa I, Engebretsen KA, Maibach H, Thyssen JP. 2017. Skin absorption through atopic dermatitis skin: a systematic review. Br J Dermatol. 177(1):84–106. doi:10.1111/bjd.15065.
   PubMed Web of Science ®Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. 2006. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 54(1):1–15. doi:10.1016/j.jaad.2005.01.010.
   PubMed Web of Science ®Google Scholar
• Hiyama H, Arichika N, Okada M, Koyama N, Tahara T, Haruta J. 2023. Pharmacological profile of difamilast, a novel selective phosphodiesterase 4 inhibitor, for topical treatment of atopic dermatitis. J Pharmacol Exp Ther. 386(1):45–55. doi:10.1124/jpet.123.001609.
   PubMed Web of Science ®Google Scholar
• Jung EC, Maibach HI. 2015. Animal models for percutaneous absorption. J Appl Toxicol. 35(1):1–10. doi:10.1002/jat.3004.
   PubMed Web of Science ®Google Scholar
• Karimkhani C, Dellavalle RP, Coffeng LE, Flohr C, Hay RJ, Langan SM, Nsoesie EO, Ferrari AJ, Erskine HE, Silverberg JI, et al. 2017. Global skin disease morbidity and mortality: an update from the global burden of disease Study 2013. JAMA Dermatol. 153(5):406–412. doi:10.1001/jamadermatol.2016.5538.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang J, Tse FL. 2011. Strategies in quantitative LC-MS/MS analysis of unstable small molecules in biological matrices. Biomed Chromatogr. 25(1-2):258–277. doi:10.1002/bmc.1572.
   PubMed Web of Science ®Google Scholar
• Linder CD, Renaud NA, Hutzler JM. 2009. Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 37(1):10–13. doi:10.1124/dmd.108.024075.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen JY, Shang HT, Liu CE, Wang Y, Niu R, Wu J, Wei H. 2010. Light microscopic, electron microscopic, and immunohistochemical comparison of Bama minipig (Sus scrofa domestica) and human skin. Comp Med. 60(2):142–148. https://pubmed.ncbi.nlm.nih.gov/20412690/.
   PubMed Web of Science ®Google Scholar
• Mehrmal S, Uppal P, Giesey RL, Delost GR. 2020. Identifying the prevalence and disability-adjusted life years of the most common dermatoses worldwide. J Am Acad Dermatol. 82(1):258–259. doi:10.1016/j.jaad.2019.09.066.
   PubMed Web of Science ®Google Scholar
• N'Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. 2009. Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res. 26(2):316–328. doi:10.1007/s11095-008-9742-9.
   PubMed Web of Science ®Google Scholar
• Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. 1999. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. Br J Anaesth. 82(6):900–903. doi:10.1093/bja/82.6.900.
   PubMed Web of Science ®Google Scholar
• Ono R, Yagi M, Shoji A, Fujita K, Yoshida M, Ports WC, Purohit VS. 2020. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 47(1):25–32. doi:10.1111/1346-8138.15123.
   PubMed Web of Science ®Google Scholar
• Ordiz I, Vega JA, Martín-Sanz R, García-Suárez O, Del Valle ME, Feito J. 2021. Transdermal drug delivery in the pig skin. Pharmaceutics. 13(12):2016. doi:10.3390/pharmaceutics13122016.
   PubMed Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, et al. 2016. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 75(3):494–503 e6. doi:10.1016/j.jaad.2016.05.046.
   PubMed Web of Science ®Google Scholar
• Pantazi E, Valenza G, Hess M, Hamad B. 2018. The atopic dermatitis market. Nat Rev Drug Discov. 17(4):237–238. doi:10.1038/nrd.2017.192.
   PubMed Web of Science ®Google Scholar
• Ramírez-Marín HA, Silverberg JI. 2022. Differences between pediatric and adult atopic dermatitis. Pediatr Dermatol. 39(3):345–353. doi:10.1111/pde.14971.
   PubMed Web of Science ®Google Scholar
• Saeki H, Baba N, Ito K, Yokota D, Tsubouchi H. 2022. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in pediatric patients with atopic dermatitis: a phase III randomized, double-blind, vehicle-controlled trial. Br J Dermatol. 186(1):40–49. doi:10.1111/bjd.20655.
   PubMed Web of Science ®Google Scholar
• Saeki H, Baba N, Oshiden K, Abe Y, Tsubouchi H. 2020. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis. J Dermatol. 47(1):17–24. doi:10.1111/1346-8138.15137.
   PubMed Web of Science ®Google Scholar
• Schrolnberger C, Brunner M, Mayer BX, Eichler HG, Müller M. 2001. Application of the minimal trauma tissue biopsy to transdermal clinical pharmacokinetic studies. J Control Release. 75(3):297–306. Doi:10.1016/s0168-3659(01)00394-7
   PubMed Web of Science ®Google Scholar
• Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, et al. 2023. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 89(1):e1–e20. doi:10.1016/j.jaad.2022.12.029.
   PubMed Web of Science ®Google Scholar
• Tom WL, Van Syoc M, Chanda S, Zane LT. 2016. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study. Pediatr Dermatol. 33(2):150–159. doi:10.1111/pde.12780.
   PubMed Web of Science ®Google Scholar
• Torres T, Ferreira EO, Gonçalo M, Mendes-Bastos P, Selores M, Filipe P. 2019. Update on Atopic Dermatitis. Acta Med Port. 32(9):606–613. doi:10.20344/amp.11963.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. 2018. Atopic dermatitis. Nat Rev Dis Primers. 4(1):1. doi:10.1038/s41572-018-0001-z.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS), et al. 2018. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 32(5):657–682. doi:10.1111/jdv.14891.
   PubMed Web of Science ®Google Scholar
• Wu J, Zheng L, Zhang Q, Zhang Q, Qin H, Zhou R, Chu Z, He G, Wang L, Hu W. 2023. LC-MS/MS determination of HY072808, a novel candidate for treating atopic dermatitis, and its active metabolite: application to a first-in-human pharmacokinetic study. Biomed Chromatogr. 37(2):e5542. doi:10.1002/bmc.5542.
   PubMed Web of Science ®Google Scholar
• Yuan L, Sophia Xu X, Ji QC. 2020. Challenges and recommendations in developing LC-MS/MS bioanalytical assays of labile glucuronides and parent compounds in the presence of glucuronide metabolites. Bioanalysis. 12(9):615–624. doi:10.4155/bio-2020-0055.
   PubMed Web of Science ®Google Scholar
• Zane LT, Kircik L, Call R, Tschen E, Draelos ZD, Chanda S, Van Syoc M, Hebert AA. 2016. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol. 33(4):380–387. doi:10.1111/pde.12872.
   PubMed Web of Science ®Google Scholar